Agents in Development for Anxiety Disorders

作者: Sean D. Hood , Spilios V. Argyropoulos , David J. Nutt

DOI: 10.2165/00023210-200013060-00004

关键词:

摘要: Benzodiazepines have been used as anxiolytics for many years, despite well described withdrawal effects and drug interactions. Serotonergic antidepressants, which benefit from a favourable adverse effect profile do not cause dependence, are now established first-line treatments anxiety disorders. It is apparent, however, that current ideal, particularly they always produce complete recovery. Our growing knowledge of the neurobiology disorders, aided by advances in neuroimaging pharmacological challenges, has led to development other potential anxiolytics. Agents with increased specificity serotonin receptor subtypes developed, aim maximising therapeutic efficacy while minimising effects. Novel anxiolytics, such neuropeptide agonists antagonists, γ-aminobutyric acid (GABA)A partial agonists, N-methyl-D-aspartate (NMDA) neurosteroids others, currently may eventually offer alternatives available agents.

参考文章(95)
A. J. Gelenberg, Julio Licinio, Ronald M. Salomon, D. S. Charney, Helen L. Miller, Pedro L. Delgado, G. R. Heninger, Monoamines and the mechanism of antidepressant action: effects of catecholamine depletion on mood of patients treated with antidepressants. Psychopharmacology Bulletin. ,vol. 29, pp. 389- 396 ,(1993)
Jelena L. Kunovac, Stephen M. Stahl, Future directions in anxiolytic pharmacotherapy. Psychiatric Clinics of North America. ,vol. 18, pp. 895- 909 ,(1995) , 10.1016/S0193-953X(18)30030-3
H. G. Baumgarten, Z. Grozdanovic, Role of serotonin in obsessive-compulsive disorder. The British journal of psychiatry. Supplement. ,vol. 173, pp. 13- 20 ,(1998) , 10.1192/S0007125000297857
Spilios V. Argyropoulos, David J. Nutt, Peptide receptors as targets for anxiolytic drugs Birkhäuser, Basel. pp. 151- 175 ,(2000) , 10.1007/978-3-0348-8470-9_11
Yves Lecrubier, The impact of comorbidity on the treatment of panic disorder. The Journal of Clinical Psychiatry. ,vol. 59, pp. 11- 14 ,(1998)
B. Aufdembrinke, Abecarnil, a new beta-carboline, in the treatment of anxiety disorders The British journal of psychiatry. Supplement. ,vol. 173, pp. 55- 63 ,(1998) , 10.1192/S0007125000293537
Joffe Rt, Bakish D, Combined SSRI-moclobemide treatment of psychiatric illness. The Journal of Clinical Psychiatry. ,vol. 55, pp. 24- 31 ,(1994)
Mendel Fux, Joseph Levine, Alex Aviv, RH Belmaker, Inositol treatment of obsessive-compulsive disorder. American Journal of Psychiatry. ,vol. 153, pp. 1219- 1221 ,(1996) , 10.1176/AJP.153.9.1219
J Gutkowska, S Merani, J Caillé, M Dépôt, J Bradwejn, G Caillé, J Mukherjee, Effect of oral ondansetron on total cholecystokinin plasma levels following CCK-4 panic challenge procedure in healthy men. Journal of Psychiatry & Neuroscience. ,vol. 23, pp. 298- 304 ,(1998)
C Ballenger James, Selective Serotonin Reuptake Inhibitors (SSRIs) in Panic Disorder 心身医学. ,vol. 41, pp. 12- 18 ,(2001)